Spots, blots, peaks and chips: Proteomic approaches in autoimmune diseases

Current Pharmaceutical Design

Volumn 12, Issue 29, 2006, Pages 3699-3706

  Dotzlaw, Helmut ^a   Eggert, M ^b   Neeck, G ^b,c   Schulz, M ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Rostock Clinic South   (Germany)

^c BIOMEDRO Biomedical Research and Development Rostock Ltd   (Germany)

Author keywords

Autoantibodies; Autoimmune disease; Protein expression pattern; Proteomics

Indexed keywords

AUTOANTIBODY;

AUTOIMMUNE DISEASE; BODY FLUID; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SEROLOGY;

ANIMALS; ARTHRITIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; HUMANS; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOMICS;

EID: 33749858416     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559704     Document Type: Review

References (57)

1. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001; 7(8): 899-905.
2. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84(3): 223-43.
3. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250(10): 4007-21.
4. Garrels JI, Gibson W. Identification and characterization of multiple forms of actin. Cell 1976; 9(4 PT 2): 793-805.
5. Lane CS. Mass spectrometry-based proteomics in the life sciences. Cell Mol Life Sci 2005; 62(7-8): 848-69.
6. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005; 4(1): 16-26.
7. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling - a young technology begins to mature. Nat Biotechnol 2005; 23(3): 291-2.
8. Hu J, Coombes KR, Morris JS, Baggerly KA. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic 2005; 3(4): 322-31.
9. Lueking A, Cahill DJ, Mullner S. Protein biochips: A new and versatile platform technology for molecular medicine. Drug Discov Today 2005; 10(11): 789-94.
10. Huels C, Muellner S, Meyer HE, Cahill DJ. The impact of protein biochips and microarrays on the drug development process. Drug Discov Today 2002; 7(18 Suppl): S119-24.
11. Angenendt P. Progress in protein and antibody microarray technology. Drug Discov Today 2005; 10(7): 503-11.
12. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39(9): 1005-29.
13. Nerup J, Mandrup-Poulsen T, Helqvist S, Andersen HU, Pociot F, Reimers JI, et al. On the pathogenesis of IDDM. Diabetologia 1994; 37(Suppl 2): S82-9.
14. Christensen UB, Larsen PM, Fey SJ, Andersen HU, Nawrocki A, Sparre T, et al. Islet protein expression changes during diabetes development in islet syngrafts in BB-DP rats and during rejection of BB-DP islet allografts. Autoimmunity 2000; 32(1): 1-15.
15. Sparre T, Christensen UB, Mose Larsen P, Fey SJ, Wrzesinski K, Roepstorff P, et al. IL-1beta induced protein changes in diabetes prone BB rat islets of Langerhans identified by proteome analysis. Diabetologia 2002; 45(11): 1550-61.
16. Larsen PM, Fey SJ, Larsen MR, Nawrocki A, Andersen HU, Kahler H, et al. Proteome analysis of interleukin-1beta - induced changes in protein expression in rat islets of Langerhans. Diabetes 2001; 50(5): 1056-63.
17. Andersen HU, Fey SJ, Larsen PM, Nawrocki A, Hejnaes KR, Mandrup-Poulsen T, et al. Interleukin-1beta induced changes in the protein expression of rat islets: a computerized database. Electrophoresis 1997; 18(11): 2091-103.
18. Nielsen K, Sparre T, Larsen MR, Nielsen M, Fey SJ, Mose Larsen P, et al. Protein expression changes in a cell system of beta-cell maturation reflect an acquired sensitivity to IL-1beta. Diabetologia 2004; 47(1): 62-74.
19. O'Hare MM, Shaw C, Swanston-Flatt SK, Marcelli M, Buchanan KD, Flatt PR. Influence of a transplantable insulinoma on the pancreatic status of insulin and pancreatic polypeptide in the rat. Diabetologia 1985; 28(3): 157-60.
20. Blume N, Skouv J, Larsson LI, Holst JJ, Madsen OD. Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. J Clin Invest 1995; 96(5): 2227-35.
21. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 2003; 302(5648): 1223-7.
22. Dieguez-Acuna FJ, Ger SA, Kodama S, Elias JE, Beausoleil SA, Faustman D, et al. Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics 2005; 4(19): 1459-70.
23. Alt C, Duvefelt K, Franzen B, Yang Y, Engelhardt B. Gene and protein expression profiling of the microvascular compartment in experimental autoimmune encephalomyelitis in C57B1/6 and SJL mice. Brain Pathol 2005; 15(1): 1-16.
24. Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, Matthieu JM, el al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995; 63(1): 17-27.
25. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994; 36 Suppl: S47-53.
26. Santiago-Raber ML, Laporte C, Reininger L, Izui S. Genetic basis of murine lupus. Autoimmun Rev 2004; 3(1): 33-9.
27. Kono DH, Theofilopoulos AN. Genetics of systemic autoimmunity in mouse models of lupus. Int Rev Immunol 2000; 19(4-5): 367-87.
28. Thebault S, Gilbert D, Machour N, Marvin L, Lange C, Tron F, et al. Two-dimensional electrophoresis and mass spectrometry identification of proteins bound by a murine monoclonal anti-cardiolipin antibody: a powerful technique to characterize the cross-reactivity of a single autoantibody. Electrophoresis 2000; 21(12): 2531-9.
29. Anthony DD, Haqqi TM. Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 1999; 17(2): 240-4.
30. Lorenz P, Bantscheff M, Ibrahim SM, Thiesen HJ, Glocker MO. Proteome analysis of diseased joints from mice suffering from collagen-induced arthritis. Clin Chem Lab Med 2003; 41(12): 1622-32.
31. Dasuri K, Antonovici M, Chen K, Wong K, Standing Y, Ens W, et al. The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res Ther 2004; 6(2): R161-8.
32. Dumont D, Noben JP, Raus J, Stinissen P, Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004; 4(7): 2117-24.
33. Ahmed M, Forsberg J, Bergsten P. Protein profiling of human pancreatic islets by two-dimensional gel electrophoresis and mass spectrometry. J Proteome Res 2005; 4(3): 931-40.
34. Ballot E, Bruneel A, Labas V, Johanet C. Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin Chem 2003:49(4): 634-43.
35. Huguet S, Labas V, Duclos-Vallee JC, Bruneel A, Vinh J, Samuel D, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 identified as an autoantigen in autoimmune hepatitis by proteome analysis. Proteomics 2004; 4(5): 1341-5.
36. Almeras L, Lefranc D, Drobecq H, de Seze J, Dubucquoi S, Vermersch P, et al. New antigenic candidates in multiple sclerosis: identification by serological proteorne analysis. Proteomics 2004; 4(7): 2184-94.
37. Lefranc D, Almeras L, Dubucquoi S, de Seze J, Vermersch P, Prin L. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J Immunol 2004; 172(1): 669-78.
38. Xiang Y, Sekine T, Nakamura H, Imajoh-Ohmi S, Fukuda H, Nishioka K, et al. Proteomic surveillance of autoimmunity in osteoarthritis: identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum 2004; 50(5): 1511-21.
39. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005; 52(9): 2645-2655.
40. Norris D. Alopecia areata: current state of knowledge. J Am Acad Dermatol 2004; 51(1 Suppl): S16-7.
41. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004; 14(6): 364-70.
42. Lucking A, Huber O, Wirths C, Schulte K, Stieler KM, Blume-Peytavi U, et al. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol Cell Proteomics 2005; 4(9): 1382-90.
43. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10(3): 245-60.
44. Avasarala JR, Wall MR, Wolfe GM. A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis: detection of three biomarkers. J Mol Neurosci 2005; 25(1): 119-25.
45. Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, et al. Mass spectrometric protcome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002; 23(19): 3445-56.
46. Drynda S, Ringel B, Kekow M, Kuhne C, Drynda A, Glocker MO, et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy. Pathol Res Pract 2004; 200(2): 165-71.
47. Hermansson M, Sawaji Y, Bolton M, Alexander S, Wallace A, Begum S, et al. Proteomic analysis of articular cartilage shows increased type II collagen synthesis in osteoarthritis and expression of inhibin betaA (activin A), a regulatory molecule for chondrocytes. J Biol Chem 2004; 279(42): 43514-21.
48. Liao H, Wu J, Kuhn E, Chin W, Chang B, Jones MD, et al. Use of mass spectrometry to identify protein biomarkets of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50(12): 3792-803.
49. Dotzlaw H, Schutz M, Eggert M, Neeck G. A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta 2004; 1696(1): 121-9.
50. Tilleman K, Van Beneden K, Dhondt A, Hoffman I, De Keyser F, Veys E, et al. Chronically inflamed synovium from spondyloardiropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics 2005; 5(8): 2247-57.
51. Miyamae T, Malehorn DE, Lemster B, Mori M, Imagawa T, Yokota S, et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res Ther 2005; 7(4): R746-55.
52. Lorenz P, Ruschpler P, Koczan D, Stiehl P, Thiesen HJ. From transcriptome to proteome: differentially expressed proteins identified in synovial tissue of patients suffering from rheumatoid arthritis and osteoarthritis by an initial screen with a panel of 791 antibodies. Proteomics 2003; 3(6): 991-1002.
53. Carlen LM, Sanchez F, Bergman AC, Becker S, Hirschberg D, Franzen B, et al. Proteome analysis of skin distinguishes acute guttate from chronic plaque psoriasis. J Invest Dermatol 2005; 124(1): 63-9.
54. Blueggel M, Chamrad D, Meyer HE. Bioinformatics in proteomics. Curr Pharm Biotechnol 2004; 5(1): 79-88.
55. Eggert M, Kluter A, Zettl UK, Neeck G. Transcription factors in autoimmune diseases. Curr Pharm Des 2004; 10(23): 2787-96.
56. Low JM, Moore TL. A role for the complement system in rheumatoid arthritis. Curr Pharm Des 2005; 11(5): 655-70.
57. Morelle W, Michalski JC. Glycomics and mass spectrometry. Curr Pharm Des 2005; 11 (20): 2615-45.